Cited 11 times in
Temozolomide Salvage Chemotherapy for Recurrent Anaplastic Oligodendroglioma and Oligo-Astrocytoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 강석구 | - |
dc.contributor.author | 장종희 | - |
dc.date.accessioned | 2014-12-18T10:01:13Z | - |
dc.date.available | 2014-12-18T10:01:13Z | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 2005-3711 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/89264 | - |
dc.description.abstract | Objective : To evaluate the efficacy of temozolomide (TMZ) chemotherapy for recurrent anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA). Methods : A multi-center retrospective trial enrolled seventy-two patients with histologically proven AO/AOA who underwent TMZ chemotherapy for their recurrent tumors from 2006 to 2010. TMZ was administered orally (150 to 200 mg/m2/day) for 5 days per 28 days until unacceptable toxicity occurred or tumor progression was observed. Results : TMZ chemotherapy cycles administered was median 5.3 (range, 1-41). The objective response rate was 24% including 8 cases (11%) of complete response and another 23 patients (32%) were remained as stable disease. Severe side effects (≥grade 3) occurred only in 9 patients (13%). Progression-free survival (PFS) of all patients was a median 8.0 months (95% confidence interval, 6.0-10.0). The time to recurrence of a year or after was a favorable prognostic factor for PFS (p<0.05). Overall survival (OS) was apparently differed by the patient's histology, as AOA patients survived a median OS of 18.0 months while AO patients did not reach median OS at median follow-up of 11.5 months (range 2.7-65 months). Good performance status of Eastern Cooperative Oncology Group 0 and 1 showed prolonged OS (p<0.01). Conclusion : For recurrent AO/AOA after surgery followed by radiation therapy, TMZ could be recommended as a salvage therapy at the estimated efficacy equal to procarbazine, lomustine, and vincristine (PCV) chemotherapy at first relapse. For patients previously treated with PCV, TMZ is a favorable therapeutic option as 2nd line salvage chemotherapy with an acceptable toxicity rate. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | JOURNAL OF KOREAN NEUROSURGICAL SOCIETY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Temozolomide Salvage Chemotherapy for Recurrent Anaplastic Oligodendroglioma and Oligo-Astrocytoma | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Neurosurgery (신경외과학) | - |
dc.contributor.googleauthor | Gwak Ho-Shin | - |
dc.contributor.googleauthor | Yee Gi Taek | - |
dc.contributor.googleauthor | Park Chul-Kee | - |
dc.contributor.googleauthor | Kim Jin Wook | - |
dc.contributor.googleauthor | Hong Yong-Kil | - |
dc.contributor.googleauthor | Kang Seok-Gu | - |
dc.contributor.googleauthor | Kim Jeong Hoon | - |
dc.contributor.googleauthor | Seol Ho Jun | - |
dc.contributor.googleauthor | Jung Tae-Young | - |
dc.contributor.googleauthor | Chang Jong Hee | - |
dc.contributor.googleauthor | Yoo Heon | - |
dc.contributor.googleauthor | Hwang Jeong-Hyun | - |
dc.contributor.googleauthor | Kim Se-Hyuk | - |
dc.contributor.googleauthor | Park Bong Jin | - |
dc.contributor.googleauthor | Hwang Sun-Chul | - |
dc.contributor.googleauthor | Kim Min Su | - |
dc.contributor.googleauthor | Kim Seon-Hwan | - |
dc.contributor.googleauthor | Kim Eun-Young | - |
dc.contributor.googleauthor | Kim Ealmaan | - |
dc.contributor.googleauthor | Kim Hae Yu | - |
dc.contributor.googleauthor | Ko Young-Cho | - |
dc.contributor.googleauthor | Yun Hwan Jung | - |
dc.contributor.googleauthor | Youn Ji Hye | - |
dc.contributor.googleauthor | Kim Juyoung | - |
dc.contributor.googleauthor | Lee Byeongil | - |
dc.contributor.googleauthor | Lee Seung Hoon | - |
dc.identifier.doi | 10.3340/jkns.2013.54.6.489 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00036 | - |
dc.contributor.localId | A03470 | - |
dc.relation.journalcode | J01520 | - |
dc.identifier.eissn | 1598-7876 | - |
dc.identifier.pmid | 24527191 | - |
dc.subject.keyword | Anaplastic oligoastrocytoma | - |
dc.subject.keyword | Anaplastic oligodendroglioma | - |
dc.subject.keyword | Chemotherapy | - |
dc.subject.keyword | Recurrence | - |
dc.subject.keyword | Temozolomide | - |
dc.contributor.alternativeName | Kang, Seok Gu | - |
dc.contributor.alternativeName | Chang, Jong Hee | - |
dc.contributor.affiliatedAuthor | Kang, Seok Gu | - |
dc.contributor.affiliatedAuthor | Chang, Jong Hee | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 54 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 489 | - |
dc.citation.endPage | 495 | - |
dc.identifier.bibliographicCitation | JOURNAL OF KOREAN NEUROSURGICAL SOCIETY, Vol.54(6) : 489-495, 2013 | - |
dc.identifier.rimsid | 34490 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.